Serologic Testing of Household Contacts of Confirmed Cases of COVID-19
Observational Trial Evaluating the Serologic Status of Household Contacts of Patients Diagnosed With COVID-19
1 other identifier
observational
96
1 country
1
Brief Summary
SARS-CoV-2 has now crossed the 1 million number of cases and tens of thousands of deaths. It´s R0 has been calculated between 2 and 5.7 solely based on clinical symptoms but it is estimated to likely be higher. Serologic evidence of infection has not been analyzed.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 26, 2020
CompletedStudy Start
First participant enrolled
May 5, 2020
CompletedFirst Posted
Study publicly available on registry
May 19, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 16, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
February 16, 2021
CompletedFebruary 18, 2021
February 1, 2021
10 months
April 26, 2020
February 16, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Identify antibodies
Identify the presence of IgM and IgG antibodies from intradomestic contacts of patients with Polymerase Chain Reaction for detected SARS-CoV-2 .
1 day
Secondary Outcomes (3)
Determine antibody sensitivity
1 day
IgM determination
1 day
IgG determination
1 day
Eligibility Criteria
The intradomiciliary contacts of the patients with a detected SARS-CoV-2 PCR test (nasopharyngeal and / or oropharyngeal swab) performed at the Acute Respiratory Infection Diagnosis Unit between March 2020 and May 2020 will be located: will invite to participate in the study to record their clinical and demographic data and to take serological samples by venipuncture or fingerstick to perform rapid tests for antibodies against SARS-CoV-2 (IVD COVID-19 IgM / IgG test kit, Singclean). Informed consent shall be obtained from each person for the collection of samples. The data collected will be captured in an electronic database in Excel.
You may qualify if:
- Persons over 1 years of age.
- Meet COVID-19 confirmed case intradomestic contact definition:
- Living in the same home as the patient with SARS-CoV-2 PCR test detected (nasopharyngeal and/or oropharyngeal swab) performed in the Acute Respiratory Infection Diagnostic Unit.
- Living in the same home as the patient with a PCR test for SARS-CoV-2 Indeterminate (nasopharyngeal and/or oropharyngeal swab) performed in the Acute Respiratory Infection Diagnostic Unit and that the initial patient has positive IgM/IgG serology for SARS-CoV-2.
- Informed Consent.
You may not qualify if:
- Have fever, cough, pharyngeal pain or clinically have symptoms compatible with COVID-19 at the time of recruitment.
- Autoimmune disease, cancer, neutropenia.
- Under 1 years of age.
- Patients who, in the investigator's opinion, should be excluded from the research protocol.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital Universitario José E. Gonzalez
Monterrey, Nuevo León, 64460, Mexico
Related Publications (4)
Maier HJ, Bickerton E, Britton P. Preface. Coronaviruses. Methods Mol Biol. 2015;1282:v. doi: 10.1007/978-1-4939-2438-7. No abstract available.
PMID: 25870870BACKGROUNDGuo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0.
PMID: 32169119BACKGROUNDHuang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
PMID: 31986264BACKGROUNDPatel A, Jernigan DB; 2019-nCoV CDC Response Team. Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020. MMWR Morb Mortal Wkly Rep. 2020 Feb 7;69(5):140-146. doi: 10.15585/mmwr.mm6905e1.
PMID: 32027631BACKGROUND
Related Links
- "About the Virus." World Health Organization, World Health Organization, 17 Apr. 2020
- "Naming the Coronavirus Disease (COVID-19) and the Virus That Causes It." World Health Organization. World Health Organization. Accessed April 17, 2020.
- Johns Hopkins Coronavirus Resource Center." Johns Hopkins Coronavirus Resource Center. Accessed April 17, 2020.
- Alocución de apertura del Director General de la OMS en la rueda de prensa sobre la COVID-19 celebrada el 11 de marzo de 2020". Organización Mundial de la Salud. Organización Mundial de la Salud. Accedido el 17 de abril de 2020
- Comparative Accuracy of Oropharyngeal and Nasopharyngeal Swabs for Diagnosis of COVID-19." CEBM. Accessed April 17, 2020.
- 12\. Cdc. "Coronavirus Disease 2019 (COVID-19)." Centers for Disease Control and Prevention. Accessed April 17, 2020
Biospecimen
Blood samples will be obtained by capillary puncture or venipuncture for rapid testing of antibodies against SARS-CoV-2 (IVD COVID-19 IgM/IgG test kit, Singclean). Samples will be stored in the laboratory, and discarded at the discretion of the researcher.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Adrian Camacho-Ortiz, MD
Hospital Universitario "Dr. Jose Eleuterio Gonzalez, UANL
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 1 Day
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of the Infectious Disease Department
Study Record Dates
First Submitted
April 26, 2020
First Posted
May 19, 2020
Study Start
May 5, 2020
Primary Completion
February 16, 2021
Study Completion
February 16, 2021
Last Updated
February 18, 2021
Record last verified: 2021-02